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Zusammenfassung
Alle zwei Jahre findet in St. Gallen (Schweiz) die internatio-
nale Konsensuskonferenz zur Behandlung des primären 
Mammakarzinoms statt. Da sich das internationale Panel in 
St. Gallen aus Experten unterschiedlicher Länder zusam-
mensetzt, spiegelt der Konsensus ein internationales Mei-
nungsbild wider. Vor diesem Hintergrund erscheint es aus 
deutscher Sicht sinnvoll, die Abstimmungsergebnisse für den 
Therapiealltag in Deutschland zu konkretisieren. Eine deut-
sche Arbeitsgruppe mit acht Brustkrebsexperten, von denen 
zwei Mitglieder des internationalen St. Gallen-Panels sind, 
hat daher die Abstimmungsergebnisse der St. Gallen-Kon-
sensuskonferenz (2013) für den Klinikalltag in Deutschland 
kommentiert. Inhaltliche Schwerpunkte der diesjährigen 
St. Gallen-Konferenz waren operative Fragestellungen der 
Brust und der Axilla, strahlentherapeutische und systemi-
sche Therapieoptionen sowie die klinische Relevanz der 
 Tumorbiologie. Intensiv diskutiert wurde der klinische Ein-
satz von Multigen-Assays, inkl. ihrer Bedeutung für die indi-
viduelle Therapieentscheidung. 
Keywords
St. Gallen Consensus · Early breast cancer · Adjuvant 
 therapy · Multigene signatures · Targeted therapy
Summary
The International Consensus Conference on the treatment 
of primary breast cancer takes place every two years in 
St. Gallen, Switzerland. The panel in St. Gallen is composed 
of international experts from different countries. From a 
German perspective, it seems reasonable to interpret the 
voting results in the light of AGO-recommendations and S3-
guidelines for everyday practice in Germany. Consequently, 
a team of eight breast cancer experts, of whom two are 
members of the international St. Gallen panel, commented 
on the voting results of the St. Gallen Consensus Confer-
ence (2013). The main topics at this year’s St. Gallen confer-
ence were surgical issues of the breast and axilla, radio-
therapeutic and systemic treatment options, and the clinical 
relevance of tumour biology. The clinical utility of multi-
gene assays for supporting individual treatment decisions 
was also intensively discussed. 
*St. Gallen Panel expert.
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Surgical Therapy
In St. Gallen, the surgical issues in primary breast cancer 
 focused on the decision criteria for or against mastectomy or 
breast-conserving therapy (BCT). The German experts criti-
cised the fact that the indication for neoadjuvant therapy was 
not discussed and refer to the current AGO recommendations 
[1]. Further topics comprised the adequate practice and 
 indications for BCT and for sentinel lymph node dissection 
(SLND) vs. complete axillary dissection (AD)
Focus on Breast-Conserving Surgery
In the votes on the absolute and relative contraindications 
against BCT, the German working-group strongly agreed with 
the majority of the decisions of the St. Gallen panel: the Ger-
man working-group emphasized that there are only relative 
and almost no absolute contraindications for BCT. One ex-
ample for a classical mastectomy indication is stage T4d. 
Young age of the patient (< 35–40 years old), multi-focal dis-
ease (per se), tumour location close to the nipple, extensive 
vascular tumour invasion, extensive intraductal component 
and lobular histology are neither absolute nor relative con-
traindications for BCT. The German working-group wel-
comes the outcome of the vote on lobular histology. The Ger-
man experts add that the surgical goal for tumours near the 
nipple is a tumour free (R0) resection, which is why a mastec-
tomy may still be necessary in certain cases. The St. Gallen 
panellists and the German working-group also agree that 
 neither a positive family history nor a prognostically un-
favourable tumour biology according to genomic analysis 
 constitutes a relative contraindication for BCT.
Extensive or scattered micro-calcifications and multicentric 
disease were deemed relative but not absolute contraindica-
tions for BCT by the majority of the St. Gallen panellists. 
From a German perspective, multicentricity is not an absolute 
contraindication for BCT, in particular if the diagnosis was 
made using magnetic resonance imaging (MRI), and the other 
imaging results (mammography, sonography) did not indicate 
multicentricity. Furthermore, the German working group 
points out that also in case of multicentric disease the surgical 
goal remains R0 resection.
The St. Gallen panel sees a relative contraindication for 
BCT with positive margins after repeated re-excisions of the 
tumour. According to the St. Gallen vote, this applies regard-
less of a residual ductal carcinoma in situ (DCIS) or an inva-
sive tumour. From a German perspective, in the case of R0 
resection of the invasive component and just focally  involved 
margins with DCIS residuals, BCT may still be an option and 
may be discussed with the patient and the radiotherapist in 
individual cases. Ideally, the invasive and non- invasive com-
ponents should be resected with free margins, and cosmesis of 
the breast should be satisfactory.
Introduction 
The St. Gallen Consensus Conference on treatment of pri-
mary breast cancer is of global relevance. The panel of this 
year’s 13th St. Gallen Consensus Conference comprised 50 
experts from a total of 19 countries, including 2 representa-
tives from Germany. The recommendations are based on the 
majority vote of the panellists, who represent different fields 
of expertise and countries from all continents with sometimes 
very different healthcare systems and resources. Under these 
circumstances, the consensus reflects an expert opinion – even 
if the individual opinions and thus ultimately the overall 
 opinion are based on published, evidence-based data. It thus 
seems reasonable from a German perspective to comment on 
the voting results. In previous years – 2009 and 2011 – this in-
terpretation taking into account the current German guide-
line recommendations was highly appreciated. Therefore, a 
team of 8 breast cancer experts commented the voting results 
of St. Gallen for everyday practice in Germany. 
Basis of the St. Gallen Consensus
This year’s St. Gallen Consensus Conference concentrated on 
topics and issues that are currently the subject of controversial 
debates within the international scientific community. The 
aim was to search for clinically applicable recommendations 
of the panellists and to:
(1) ideally reach a consensus; 
(2) take into account country-specific differences;
(3) define issues that need to be clarified within on-going and 
future controlled clinical trials.
In their preparation of the St. Gallen consensus conference, 
the panellists agreed that controlled clinical trials are suitable 
to document the clinical benefit of one treatment over an-
other and to define the average outcome improvement for 
 patients. However, they are unable to make any definitive 
statements on the specific treatment benefit for an individual 
patient. 
In summary: every treatment decision must be made indi-
vidually. The basis for the treatment choices in primary breast 
cancer are tumour biology, tumour size, lymph node involve-
ment and patient’s preference. Tumour biology defines the 
response probability for a given therapy and, along with 
 tumour size and lymph node involvement, indicates the thera-
peutic benefit that can be expected.
The St. Gallen panellists answered the questions with ‘yes’ 
(agreement), ‘no’ (rejection) or ‘abstention’. The latter is 
meant to indicate insufficient data available or no opinion 
possible due to a lack of expertise in this field for the individ-
ual panellist or a conflict of interest. The votes were given 
with the understanding that individual deviations may be nec-
essary in individual cases.
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Moreover, there is a relative contra-indication for BCT if 
the patient is unable to receive post-operative irradiation. The 
German working group agrees with the clear vote of the 
St. Gallen panellists. The German experts criticise the ab-
sence of a vote on inflammatory breast cancer (IBC, defined 
as signs of inflammation of the breast skin of more than 30% 
of the skin and histologically proven invasive cancer), which 
constitutes a relative contraindication for BCT according to 
the AGO recommendations [1]. After neoadjuvant chemo-
therapy with a complete pathological remission, BCT may be 
performed in individual cases with IBC (AGO recommenda-
tion +/–).
There were close votes on BRCA1/2 mutation carriers and 
surgery for primary breast cancer patients. A BRCA1/2 muta-
tion was considered a relative contraindication for BCT with 
only a narrow majority. The German experts interpret this 
close vote as illustrative of the existing controversy. The Ger-
man working group would not base the indication for or 
against BCT solely on BRCA 1/2 mutation status. According 
to the 2013 AGO recommendation this should be decided in-
dividually [1]. The German experts point out that the patient’s 
request for a  contra-lateral prophylactic mastectomy should 
be taken into consideration.
Focus on mastectomy
Just under two thirds of the St. Gallen panellists answered 
‘yes’ to the question as to whether a nipple-sparing mastec-
tomy is acceptable if the patient is not irradiated postsurgi-
cally. More than half of the panellists only accepted this in 
case of a tumour-free margin behind the nipple and an imme-
diate reconstruction of the breast; regarding the latter issue, 
almost a third of the panellists abstained. The German work-
ing group commented that a R0 resection is always mandatory 
in this situation and that the indication for post-surgery radia-
tion is independent of a primary or secondary reconstruction. 
If post-surgery radiotherapy to the chest wall is indicated, an 
immediate reconstruction, especially using implants, would 
not be a good choice.
The St. Gallen panellists and the German working group 
agreed that MRI is not a routine procedure for the decision 
‘BCT versus mastectomy’ in newly diagnosed patients.
Focus on ‘Margins’
Invasive primary breast cancer must be resected with tumour-
free margins (R0). 72.9% of the St. Gallen panellists opted for 
no ink on the invasive tumour cells and 48.1% for a minimal 
surgical margin of 1 mm. This also corresponds to the require-
ments in the current AGO recommendations [1]. The Ger-
man working group points out that, unlike with DCIS, the 
width of tumour free margins (1 mm or more) is not clinically 
relevant in patients with invasive cancer. This applies irre-
spective of the under lying tumour biology [2]. The St. Gallen 
panellists emphasise with a majority of 77.6% that tumour 
 biology is not clinically relevant in this context. Nonetheless, 
it remains unclear as to whether this also applies to patients 
with triple-negative primary breast cancer who have a sub-
stantially increased risk of local relapse [2, 3]. For ‘DCIS’ as 
sole diagnosis, the AGO requests a tumour-free margin of 
≥ 2 mm in case of BCT. This is also the opinion of the major-
ity of the St. Gallen panellists.
Indication for an Axillary Dissection?
The St. Gallen panellists agreed that in patients with 1 or 2 
positive sentinel lymph nodes (SN) receiving a mastectomy 
axillary dissection (AD) must be completed. Over 90% of the 
panellists opted for a complete axillary dissection if no irradi-
ation is planned post-surgery and 50% opted for AD in pa-
tients with mastectomy and with post- surgery irradiation. The 
German working group stresses that a complete axillary dis-
section should be performed independently of whether or not 
the patient is irradiated after mastectomy. AD can only be 
omitted in case of 1 or 2 involved sentinel lymph nodes 
 according to the ACOSOG Z 0011study criteria [4] (BCT, 
tangential field radiation, adequate systemic therapy) and not 
in patients with mastectomy (with or without post-surgery 
 irradiation). Adjuvant irradiation of the axilla in case of posi-
tive sentinel lymph nodes is not an evidence-based alternative 
to axillary dissection. 72.7% of the St. Gallen  panellists voted 
against AD in patients with BCT plus adjuvant irradiation, if 
only 1–2 SN are involved. According to the German experts, 
with reference to the current AGO recommendations [1], this 
is an individual decision that should be discussed with the 
 patient individually. AD is no longer routine practice in this 
situation (AGO +/–).
The majority of the St. Gallen panellists agreed that pa-
tients with BCT require a complete axillary dissection if they 
have clinically apparent lymph nodes (cN1) or ≥ 3 involved 
sentinel lymph nodes. The German working group agrees. 
According to the German experts these patients were not en-
rolled into the ACOSOG Z0011 study [4].
More than half of the St. Gallen panellists (59%) see an 
indication for complete AD if the number of positive lymph 
nodes is relevant for  adjuvant chemo- or radiotherapy. This 
vote was controversially discussed among the German ex-
perts. According to the current AGO recommendations [1], 
the chemotherapy indication does not primarily depend on 
number of positive lymph nodes, but rather on the underlying 
tumour biology. Nonetheless, AD can be performed if the 
type of chemotherapy  depends on the absolute number of 
positive lymph nodes.
Focus on radiotherapy
Radiation after Breast-Conserving Surgery
The German working group agreed with the majority of 
the St. Gallen panellists (68%) that not all patients with 
BCT need adjuvant radiotherapy. However, the German 
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pN0 R0, PMRT can be omitted if no additional risk factors 
are present (AGO +/–).
PMRT is not a standard therapy in case of pathologically 
tumour-free lymph nodes (pN0). The St. Gallen panellists and 
the German working group agree that this also applies if 
< 8 lymph nodes had been removed. Moreover, PMRT – re-
gardless of nodal status – is not necessarily indicated in young 
patients (< 40 years) or if a G3 tumour, lympho-vascular inva-
sion, HER2 positivity or triple negative breast cancer (TNBC) 
are present. The German  experts agree and add that an indi-
cation in node-negative  patients for PMRT should be based 
on additional risk factors (see above).
Irradiation of the Nodal Areas
The St. Gallen panellists and the German working group 
agree that the indication for adjuvant irradiation of the nodal 
areas does not depend on the intrinsic sub-type of breast 
 cancer or on the response to neoadjuvant chemotherapy 
(NACT). The German experts point out that there are no 
data, and therefore the decision needs to be made individu-
ally. There is also a consensus that adjuvant irradiation of the 
nodal areas is not automatically indicated and does not neces-
sarily include the axilla and the internal mammary lymph 
nodes. Moreover, the St. Gallen panellists rejected by a 
 majority that irradiation of suprainfraclavicular fields (SICF) 
(82%) and the internal mammary lymph nodes (70%) needs 
to be routinely performed in case of an indicated nodal 
 irradiation (53%). With reference to the AGO [1], the Ger-
man experts recommend SICF irradiation for patients with 
pN2a and (p)N3a-c tumours and only in individual cases in 
stage pN1a. SICF irradiation is also recommended if level III 
lymph nodes are affected or if axillary surgery cannot reach 
R0 margins.
Focus on Pathology
Difference between Luminal A and Luminal B Carcinomas
For practical purposes, in order to reliably distinguish be-
tween luminal A and luminal B type breast cancer (HER2-
negative), the proliferation marker Ki-67 can be used in 
 addition to the hormone receptor status (ER, PgR). The 
St. Gallen panellists and the German working group were in 
agreement that tumour grade only constitutes an unsatisfac-
tory substitute for Ki-67. However, the German experts add 
that the Ki-67 value should be consistent with grade in order 
to make a therapeutic decision; especially G3 should correlate 
with a high Ki-67 value.
According to the majority vote of the St. Gallen panellists 
(60%), the use of molecular diagnostics for distinction be-
tween luminal A and luminal B tumours is not necessary in 
everyday practice. The German experts agree and add that 
 experts point out that this patient group is not clearly defined. 
Omission of irrradiation may be justifiable in elderly and 
 co-morbid patients with a limited life expectation (< 10 years) 
and low-risk cancer.
A majority of the St. Gallen panellists (59.2%)  considered 
hypofractionated (‘short course’) irradiation with 45 Gy 
 administered in 15 fractions, a standard option for all BCT 
 patients with primary breast cancer. Over two thirds of the 
St. Gallen panellists (72.2%), however, saw hypofractionated 
irradiation as a standard option for selected patients. The 
German working group welcomes both votes. From a German 
perspective, consideration of this recommendation by Ger-
man radiotherapists is highly desirable. The recommendation 
is based on the current updated results of the START trials 
from the United Kingdom [5]. The indication should corre-
spond to the inclusion criteria of these trials. Hypofraction-
ated irradiation is also an option if boost irradiation is 
planned. Here, too, the German working group agreed with 
the St. Gallen vote.
Exclusive intraoperative (partial breast) irradiation is 
not standard of care in case of breast-conserving surgery. 
This is clearly stated in the current AGO recommendations 
(AGO: –) [1] and is also in line with the St. Gallen vote. 
 Exclusive  intraoperative irradiation may only be an option in 
case of  favourable tumour biology. In the AGO recommenda-
tions 2013 [1], intraoperative irradiation is an option for 
 replacing an external postoperative boost (AGO +).
Radiation of the Thoracic Wall and  
Regional Nodes after Mastectomy
In patients after mastectomy, adjuvant irradiation is the 
 standard of care in case of at least 4 positive lymph nodes 
(chest wall and suprainfraclavicular field (SICF). Over 95% 
of the St. Gallen panellists voted in favour of this. In case of 
1–3 positive lymph nodes, adjuvant irradiation to the chest 
wall is not routinely indicated – unless there are additional 
risk factors such as large tumour size, unfavourable tumour 
biology, or young age (< = 40 years). The German working 
group agrees with the vote and adds that in particular young 
women with unfavourable tumour biology should additionally 
receive postmastectomy radiotherapy (PMRT).
According to the St. Gallen vote, PMRT is also indicated 
in patients with positive SN but no AD. The German working 
group does not agree because adjuvant radiotherapy cannot 
substitute an otherwise indicated AD. From a German per-
spective, adjuvant radiotherapy is not an alternative to a com-
plete AD in case of positive SN.
PMRT is standard of care for patients with large primary 
tumours of > 5 cm, independent of the nodal status. The Ger-
man working group agrees, referring to the AGO recommen-
dations [1]. In case of pT3/4 carcinomas, the AGO strongly 
recommends PMRT (AGO ++). Only in patients with pT3 
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there is no routine indication for gene signatures in Germany. 
There is a consensus that a molecular and histopathological 
diagnosis should always be performed in a quality-controlled 
pathology laboratory to obtain reliable test results.
HER2 Positivity
Patients with a positive HER2 status (HER2 overexpression) 
additionally require an anti-HER2 therapy. HER2-positive 
breast cancer is defined as ≥ 30% of immuno-histochemically 
proven tumour cells stained positive for HER2 (IHC3+) and/
or a FISH ratio of ≥ 2.0. In case of an HER2 expression of 
> 10% to < 30% (IHC2+), an additional FISH analysis is 
 recommended. If there is amplification in the FISH analysis, 
heterogeneity of HER2 overexpression is not therapeutically 
relevant. For an anti-HER2 therapy, hormone receptor status, 
proliferation activity of the tumour and polysomy 17 are 
not relevant. The  German working group agrees with the 
St. Gallen panel on all of these points.
Chemotherapy Indication
The St. Gallen panel and the German working group agree 
that the intrinsic breast cancer sub-type has an influence on 
the indication for adjuvant chemotherapy. The intrinsic sub-
type can be classified reliably by the criteria of St. Gallen 2011 
– based on the hormone receptor and HER2 status, grade, 
and Ki-67. Classification using multi-gene expression analyses 
is not indicated for every day practice. From a German 
 perspective, however, the cut-off value of Ki-67 for high pro-
liferation still remains unclear. The cut-off value of 14% as 
defined by the 2011 St. Gallen Consensus was questioned by 
this year’s St. Gallen panel and is also not sufficiently vali-
dated from a German perspective. An increase in the  cut-off 
value to 20% is currently being discussed. This was also sug-
gested by the St. Gallen panel this year. From the German 
experts’ perspective, the Ki-67 value represents a continuum.
Clinical Relevance of Multi-Gene Assays
In hormone-sensitive primary breast cancer (ER+ and/or 
PgR+), the question remains if patients also need chemother-
apy in addition to endocrine therapy. Over 97% of the 
St. Gallen panellists rejected an additional multi-gene assay 
for the majority of patients after the clinical and pathological 
determination of the intrinsic sub-type. No additional multi-
gene assay is routinely indicated in case of a positive oestro-
gen (ER) and/or positive progesterone (PgR) receptor status. 
This also applies – according to a simple majority of the 
St. Gallen panellists – to patients with a luminal B sub-type 
(HER2-negative). From a German perspective, a multi-gene 
assay is only justified if the intrinsic classification – luminal B 
or luminal A – is uncertain and the chemotherapy indication 
strongly depends upon it.
Likewise, a multi-gene assay is not indicated in patients 
with hormone-sensitive HER2-negative breast cancer and 
positive lymph nodes. The German experts add that in case of 
lymph node involvement, chemotherapy is recommended. 
This is different in primary breast cancer patients with only 
0–3 involved lymph nodes and a positive ER status without 
HER2 overexpression. In this case, a simple majority of the 
St. Gallen panellists sees an indication for a multi-gene assay. 
The German working group sees an indication for a multi-
gene assay mostly in the sub-group of patients with G2 carci-
nomas, a mid-range Ki-67 value (15–20%) and slightly posi-
tive ER/PR as the chemotherapy indication in these patients 
is uncertain. From a German perspective, uPA/PAI-1 meas-
urement is a valid and evidence-based alternative to the 
multi-gene assay in N0 patients. For patients with node-nega-
tive G2 cancer this assay is widely used in Germany, but was 
not discussed by the St. Gallen panellists.
Different Multi-Gene Assays 
Different multi-gene assays are used in ongoing clinical trials. 
The most widely used genomic test is currently the 21-gene 
recurrence score (RS) (Oncotype DX®). Accordingly, the 
 majority of the St. Gallen panellists see the 21-gene RS as the 
only option for routine use for HR-positive patients and an 
unclear chemotherapy indication. Further options, such as the 
PAM50 assay, the 70-gene signature (Mammaprint®), the 
 EPClin score (EndoPredict®) and Mammostrat®, were re-
jected by the majority of the St. Gallen panel with respect to 
indicate (or spare) adjuvant chemotherapy.
The German working group does not agree with these 
votes and points out that Oncotype DX and EndoPredict 
have a similar ‘level of evidence’ (loe) according to the actual 
AGO recommendations. Furthermore there are no prospec-
tively validated data for any of these multi-gene assays. 
 Oncotype DX, EndoPredict, Mammaprint, Pam50 and 
 Mammostrat should thus only be used in individual cases [1] 
until prospective validation is available. Again the German 
experts point out that uPA/PAI-1 is a well-validated test 
method for node-negative G2 cancer to confirm a chemother-
apy indication. PAM50 and EPClin are tests retrospectively 
validated on tumours from the ATAC and ABCSG studies. 
They are able to distinguish between patients with a good and 
a poor prognosis. However, data showing that those patients 
with a poor prognosis derive benefit from adjuvant chemo-
therapy are still missing. Consequently, both tests are not suit-
able to verify a chemotherapy indication. Prospective valida-
tion is also lacking for the 70-gene signature. The German 
 experts explicitly warn against ‘test hopping’. It has been 
demonstrated that tests may show different results in 20–30% 
even if they were performed on the tumour material from the 
same patient (uPA/PAI-1 and Oncotype DX in the Plan B 
Study [8] as well as Pam 50 and Oncotype DX [9]). uPA/
PAI-1 and Oncotype DX showed a good correlation only in 
the high-risk group.
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Adjuvant Antihormonal Treatment
Premenopausal Patients
For premenopausal patients with hormone-sensitive  primary 
breast cancer, tamoxifen is standard. The German working 
group agrees with the majority of the panellists in 
St. Gallen. A combination with ovarian suppression (OFS) 
was rejected by the majority and the panel’s vote was divided 
in the case of patients under 40 years of age: half voted for the 
addition of OFS, half against. The German experts specify 
that, according to the studies available, the combination of ta-
moxifen plus OFS (mainly gonadotropin releasing hormone 
(GnRH) analogues) is not superior to tamoxifen. According 
to the current AGO recommendations, the addition of OFS 
to tamoxifen may be an option only for patients with a low 
or intermediate risk who have not received any additional 
chemotherapy. Young age (e.g. < 40 years old) per se is not a 
reason to perform OFS in addition to tamoxifen. 70% of the 
St. Gallen panellists rejected the exclusive use of OFS (with-
out tamoxifen) as a therapeutic option. The German working 
group disagrees and refers to the AGO recommendations [1]. 
The exclusive use of OFS is an option for patients with a 
 contraindication to tamoxifen. This is a better option than no 
endocrine therapy at all. 
From a German perspective, tamoxifen for 10 years should 
be discussed also with every premenopausal patient, weighing 
benefits against risks. For patients with an increased relapse 
risk (e.g. N+) and those without significant side effects from 
tamoxifen, the longer duration of the therapy is an important 
new therapeutic option. In the AGO recommendations, ad-
ministration of tamoxifen is recommended for up to 10 years. 
The German working group agrees with the St. Gallen vote.
The majority of the St. Gallen panellists rejected the use of 
aromatase inhibitors (AI) in premenopausal patients in addi-
tion to OFS. However, it is an option if there are contraindi-
cations to tamoxifen (e.g. thrombosis, embolism). This corre-
sponds to the evaluation according to the AGO recommenda-
tion (AGO +/–) [1]: the AI/OFS combination is an option for 
premenopausal patients in individual cases. The German 
working group agrees, but points out that OFS is also an 
 option in patients with contraindications to tamoxifen (see 
above).
Postmenopausal Patients
The votes on endocrine treatment in postmenopausal patients 
focused on the use of tamoxifen and AI with particular em-
phasis on therapy duration. The St. Gallen panellists voted 
with a clear majority (93.6%) that the exclusive administra-
tion of tamoxifen still constitutes an option for postmeno-
pausal patients with hormone-sensitive primary breast cancer. 
The German working group agrees. There can be an indica-
tion for tamoxifen alone in the case of older patients, intoler-
ance to AI, pronounced osteoporosis or low relapse risk 
(small tumour, N0, G1/2). 
Molecular Diagnostics …
… for Hormone-Sensitive Primary Breast Cancer
The St. Gallen panellists voted by a majority that molecular 
diagnostics in patients with hormone-sensitive primary breast 
cancer are not necessary in the following cases: 
– very small tumours (≤ 1 cm), where no chemotherapy is 
indicated at all;
– large tumours (e.g. > 5 cm), where there is an indication for 
chemotherapy;
– inflammatory carcinomas that also always have a chemo-
therapy indication;
– very low oestrogen receptor expression (e.g. 5%), as chemo-
therapy is indicated in addition to endocrine treatment.
While the German working group agrees with each of the 
St. Gallen votes, it points out that tumour size per se is not 
a sufficiently validated factor for a chemotherapy indication 
alone and that other factors need to be taken into 
consideration.
The St. Gallen panellists did not vote in favour of the 
 statement that molecular diagnostics can be omitted in 
 patients with hormone-sensitive primary breast cancer and 
1–3 involved lymph nodes because these patients require 
chemotherapy anyway. The German working group points 
out that 1–3 involved lymph nodes constitute a relative but 
not an absolute chemotherapy indication. This chemotherapy 
indication should be decided upon individually – depending 
on tumour biology. The decision for or against chemotherapy 
should be based on additional factors. 
In the case of 4 or more involved lymph nodes, however, 
molecular testing is not necessary as there is a chemotherapy 
indication, as the St. Gallen panellists and the German ex-
perts established unanimously. The German experts add that 
the 21-gene RS has not yet been prospectively validated in 
node-positive patients.
The German working group and the St. Gallen panel are 
not in agreement regarding patients with hormone-sensitive 
primary breast cancer and a G3 tumour, as well as very young 
women (< 35 years old) and the use of molecular diagnostics: 
the majority of the St. Gallen panellists decided that molecu-
lar diagnostics may be useful in these cases. The German 
working group does not see an indication for molecular test-
ing in either case. From a German perspective, there is a 
chemotherapy indication for a G3 tumour and in very young 
women.
Influence of the Stroma
Pathological properties of the stroma, such as lymphocyte 
 infiltration, microvascular density and p16 staining of the 
stroma, have no influence on treatment decisions. The 
St. Gallen panellists agreed upon this by a clear majority and 
the German working group also agrees. 
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positive node’) is therefore insufficient as a sole factor for a 
chemotherapy indication. If, however, at least 4 lymph nodes 
are histologically affected, patients are at increased risk and 
chemotherapy needs to be given. Lympho-vascular invasion 
in itself does not constitute a chemotherapy indication. In 
young patients (i.e. < 35 years old), the German experts rec-
ommend weighing benefits against risk in consultation with 
the informed patient. This is in line with a highly ambivalent 
St. Gallen vote (more than half voted against chemotherapy 
solely based on the young age).
Luminal A Sub-Type
Numerous votes in St. Gallen focussed on the influence of the 
intrinsic breast cancer sub-type on the choice of cytostatic 
therapy. Luminal A breast cancers belong to the highly endo-
crine sensitive tumours. The St. Gallen panellists and the 
 German experts agreed that the luminal A subtype is less 
 sensitive to chemotherapy and thus should rather be treated 
by endocrine therapy alone. In the case of an increased risk, 
however, there may be a chemotherapy indication. In this 
case, from a German perspective it is inadequate to preferen-
tially treat the patients with a less intensive regimen, such as 
4×AC, 6×CMF or 4×TC. The German working group thus 
disagrees with the majority St. Gallen vote (62%), which 
deemed less intensive chemotherapy to be sufficient for lumi-
nal A breast cancer. The German experts explain their dis-
agreement with the St. Gallen vote by stating that a chemo-
therapy indication requires an increased risk of relapse, which 
in turn requires chemotherapy with optimum efficacy. The 
 patients should receive an anthracycline/taxane-based combi-
nation or sequence for at least 18–24 weeks.
Luminal B Sub-Type
Hormone-receptor-positive patients with luminal B breast 
cancer (HER2-negative) have an increased risk of relapse and 
are sensitive to chemotherapy because of their increased pro-
liferation rate. Patients with luminal B breast cancer (HER2-
negative) thus need to receive chemotherapy prior to endo-
crine treatment. The Ki-67 measurement is useful  according 
to the St. Gallen panellists to define the ‘luminal B’ sub-type. 
The majority of the St. Gallen panellists see the Ki-67 cut-off 
value at ≥ 20%. The majority of the German  experts are also 
in favour of Ki-67 ≥ 20% as a threshold, but stress the contin-
uum of the value.
The St. Gallen panellists voted by a majority in favour of 
anthracycline and taxane based regimen for patients with a 
 luminal B sub-type for at least 6 cycles in case of a chemo-
therapy indication. The German group agrees and point out 
that an 18–24-week course of therapy is standard. Dose-dense 
chemotherapy can be indicated in the case of at least 4 in-
volved lymph nodes. In the event of a luminal B tumour with 
HER2 overexpression, the patients require chemotherapy 
with trastuzumab.
If an AI is indicated, 47.5% of the St. Gallen panellists 
would already administer it upfront and 50% would not. The 
German working group agrees with the narrow majority of 
50% of the panellists who do not see any compelling ‘upfront’ 
indication for AI in general. However, if there is a risk situa-
tion (pN+), the St. Gallen panellists (87.2%) and the German 
experts agreed that upfront AI is indicated. 
They were also in agreement on the following votes: after 
upfront administration of the AI, it can be switched to 
 tamoxifen. A majority of the St. Gallen panellists answered 
‘yes’ to the question as to whether patients who had already 
received anti-hormonal therapy for 5 years should be offered 
further treatment with an AI for node-positive but not for 
node-negative patients. The German working group agrees 
with this statement but points out that no valid data on the 
use of an AI for > 5 years are available so far. The decision 
should thus be made individually by weighing the benefits 
against risks. 
Further endocrine treatment with an AI is both an option 
after 5 years of tamoxifen and after tamoxifen and a switch to 
AI within the first 5 years. Once again, the German experts 
pointed out that no data are available from controlled clinical 
trials that justify the use of an AI beyond 5 years. Accord-
ingly, both the St. Gallen and the German experts rejected 
further treatment with AI for patients who already received 
an AI ‘upfront’ for 5 years. They agreed that in the case of 
contraindications against AI and after upfront administration 
of tamoxifen over 5 years, tamoxifen can be used subse-
quently for (another) 5 years. The AGO recommends to give 
tamoxifen to patients at increased risk of relapse for up to 
10 years (AGO ++) [1].
Several studies with longer endocrine treatment are on-
going. Also there is a need for multigene signatures to predict 
late relapse.
Adjuvant Chemotherapy
Chemotherapy Indication
The St. Gallen panellists and the German working group 
agree that high grade (G3 tumour), an increased Ki-67 value, 
low ER expression and invasive ductal triple negative breast 
cancer (TNBC: ER-, PgR-, HER2-) are indicators for adju-
vant chemotherapy. For Ki-67, the lack of methodological 
standardization and the cut-off value controversy are prob-
lematic. The individual high-risk classification obtained by the 
two genomic tests, 21-gene RS (Oncotype DX) and 70-gene 
test (Mammaprint) were deemed additional indicators for 
chemotherapy. There was no voting on other molecular tests 
(Pam 50, EndoPredict) for evaluation of chemotherapy 
indication.
The lymph node status has no predictive value, but is still 
regarded as a prognostic factor. A positive nodal status (‘any 
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Anti-HER2 Therapy
72.5% of the St. Gallen panellists see an indication for an 
anti-HER2 therapy with trastuzumab in case of HER2-posi-
tive primary breast cancer with an invasive tumour of 5 mm or 
larger; 17.5% see an indication for anti-HER2 therapy irre-
spective of the size of the primary tumour. Trastuzumab 
should be used simultaneously with taxanes, but not necessar-
ily simultaneously with anthracyclines. For both votes, there 
was a clear majority on the St. Gallen panel. The German ex-
perts also agree with both votes. If there are contraindications 
to chemotherapy, 50% of the St. Gallen panellists voted for 
and 50% against the exclusive treatment with trastuzumab 
(without chemotherapy). The German working group points 
out that there are no data and no registrational approval for 
administration of trastuzumab without chemotherapy (± anti-
hormonal treatment). 
Neoadjuvant Systemic Therapy
Neoadjuvant Chemotherapy 
Half of the St. Gallen panellists (50.9%) consider improve-
ment of the local (surgical) therapeutic options as the primary 
goal of neoadjuvant chemotherapy (NACT). The German 
 experts would like to extend this statement. The response 
 associated with the NACT enables early evaluation of indi-
vidual benefit from systemic therapy and thus contributes to a 
stronger individualisation of the treatment. Moreover, NACT 
facilitates prognostic evaluation. Achieving a pathological 
complete remission (pCR) is regarded as a strong prognostic 
marker for long-term survival in the case of HER2-positive 
tumours and TNBC. 
Patients who achieve a pCR after NACT do not require 
any further chemotherapy post-surgery (adjuvant). According 
to the St. Gallen vote, this is also true for patients who have 
not achieved a pCR after NACT. The German experts agree 
in both cases, but admit that there is no indication for further 
adjuvant chemotherapy in the case of no pCR if all chemo-
therapy cycles were administered preoperatively. If not all 
 cycles had been administered preoperatively, the chemother-
apy should be completed in the adjuvant setting even if a pCR 
has been achieved. Future studies need to verify if further 
chemotherapy is needed in this situation. In summary, all 
chemotherapy cycles should be administered preoperatively. 
HER2-Positive Breast Cancer
In case of HER2-positive primary breast cancer, the patients 
need an anti-HER2 therapy as part of the neoadjuvant ther-
apy in addition to chemotherapy. A dual HER2 blockade is 
currently not indicated, formal approval is pending.
HER2-Positive Sub-Type
Patients with HER2-positive primary breast cancer require 
anti-HER2-therapy in addition to chemotherapy. The St. Gal-
len panellists and the German experts agree that there is no 
preferred chemotherapy regimen in case of HER2-positivity 
but that chemotherapy should contain an anthracycline and a 
taxane. The majority is in favour of a simultaneous taxane and 
trastuzumab administration. Also from a German perspec-
tive, the trastuzumab therapy should be carried out simulta-
neously with the taxane. 
Invasive Ductal Triple Negative Breast Cancer
Patients with triple negative breast cancer (TNBC) have an 
unfavourable prognosis. The St. Gallen panellists voted in 
 favour of treating these patients with chemotherapy that con-
tains an anthracycline and taxane. Alkylating agents in high 
doses or platinum salts, however, should not be recom-
mended. Whether patients with invasive ductal TNBC should 
preferentially be treated with dose-dense chemotherapy was 
rejected by the St. Gallen panellists: 38.3% voted in favour 
and 48.9% rejected preferential dose-dense chemotherapy. 
The German experts agreed with the individual votes on inva-
sive ductal TNBC. While benefits from dose-dense therapy 
could be demonstrated in a German phase III trial also for 
patients with TNBC [10], no preferred indication for a dose-
dense therapy can be derived.
Other Criteria for Special Chemotherapy Regimen?
The chemotherapy decision is fundamentally influenced by 
tumour-related characteristics. The St. Gallen panellists and 
the German working group agreed that, on top of this, poten-
tial co-morbidities play a key role for the chemotherapy indi-
cation and the choice of regimen. Moreover, the biological 
age of the patient should be taken into consideration. The 
preservation of the ovarian function and fertility that is often 
desired by young patients is not always possible. The German 
experts point out that specific preservation of fertility as well 
as ovarain function cannot be guaranteed. Every chemother-
apy can compromise fertility. However, there are chemother-
apies that are potentially more harmful to the ovaries than 
others. If justifiable, the cyclophosphamide dose should be 
kept as low as possible and preferably an anthracycline and 
taxane-containing regimen should be used. From a German 
perspective, it should be noted that the efficacy of the treat-
ment is important particularly in young women and should 
have priority. Possible alopecia is not a reason against an 
 effective chemotherapy. The intrinsic sub-type does not 
 influence the type of chemotherapy. However, the German 
experts refer to the current AGO recommendations [1] re-
garding chemotherapy in certain sub-types. There is also no 
specific chemotherapy regimen that should preferably be used 
in BRCA  mutation carriers.
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There is currently no adjuvant indication for the RANK li-
gand denosumab. Data that justify a substitution of deno-
sumab for zoledronate as adjuvant treatment are not available 
yet. The issue should be clarified in studies. 
Follow-Up Examination
Patients with breast cancer should undergo regular follow-up 
examinations after the end of the primary treatment (surgery, 
radiation and chemotherapy, antibody and/or antihormone 
therapy). This requires personal visits to the physician and 
should not be carried out over the telephone. However, col-
leagues from Great Britain see a possibility for follow-up vis-
its by specialised nurses. For the time being, such a situation is 
hardly conceivable for Germany, but should be verified in 
studies. With the exception of mammography and breast ul-
trasound, routine imaging is not indicated for patients without 
symptoms during follow-up.
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Neoadjuvant Endocrine Therapy
There is a broad consensus that exclusive neoadjuvant endo-
crine therapy may be a reasonable therapeutic option for 
postmenopausal patients with highly hormone-sensitive 
breast cancer (high hormone receptor expression, low prolif-
eration index). The German experts agree. A majority (62.2%) 
of the St. Gallen panellists voted in favour of continuing neo-
adjuvant treatment therapy to its maximum response instead 
of limiting it to 3 or 4 months. The German working group 
agreed with the majority vote.
Adjuvant Use of Bisphosphonates
The questions in St. Gallen focussed on the bisphosphonate 
zoledronate. The majority of the St. Gallen panellists (70%) 
voted against adjuvant administration of zoledronic acid 
(every 6 months) in addition to adjuvant  endocrine therapy to 
prolong disease-free survival. The German experts agree. The 
St. Gallen panellists rejected adjuvant treatment with zole-
dronic acid both for  premenopausal patients who receive 
 adjuvant tamoxifen ± GnRH agonists and postmenopausal 
patients with hormone-sensitive breast cancer. The German 
experts agree. They see an exception for premenopausal pa-
tients who meet the inclusion criteria of the ABCSG 12 study 
[11, 12]. However, it should be pointed out that bisphospho-
nates were given for 3 years. In postmenopausal patients, the 
German experts disagree with the St. Gallen vote based on 
the clinical data available. The AGO (AGO +) [1] recom-
mends adjuvant administration of zoledronate (AGO EG +) 
for postmenopausal patients with ER-positive breast cancer. 
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